There are 2789 resources available
837P - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience
Presenter: Salman Soomar
Session: ePoster Display
839P - Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US
Presenter: Patrick Connor Johnson
Session: ePoster Display
840P - Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Presenter: Yuan-Kai Shi
Session: ePoster Display
841P - IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Presenter: Keyu Li
Session: ePoster Display
842P - Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models
Presenter: Alberto Arribas
Session: ePoster Display
843P - Characteristics and outcomes of ocular adnexal lymphomas: Experience of a tertiary cancer care center over 16 years
Presenter: Inês Oliveira
Session: ePoster Display
844P - Barriers to treatment for patients with lymphoma across Europe: Upper middle income versus high income countries
Presenter: Olufunmilayo Bamigbola
Session: ePoster Display
845P - Incidence of second primary malignancies (SPM) in relapsed/refractory (r/r) B-cell non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) patients in England
Presenter: Montserrat Miret
Session: ePoster Display
846P - Predictive and prognostic values of serum VEGF in patients with multiple myelomas receiving bortezomib-based therapy
Presenter: Salah Khallaf
Session: ePoster Display